as 11-15-2024 4:00pm EST
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system, as well as Canine Health, a companion pet supplement formulated to combat oxidative stress in dogs. Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | LEHI |
Market Cap: | 127.0M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 121.1K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
EPS: | 0.32 | EPS Growth: | 59.77 |
52 Week Low/High: | $5.05 - $15.15 | Next Earning Date: | 10-29-2024 |
Revenue: | $196,014,000 | Revenue Growth: | -7.97% |
Revenue Growth (this year): | 4.36% | Revenue Growth (next year): | 3.85% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Lewis Darwin | LFVN | Director | Sep 17 '24 | Buy | $10.27 | 351 | $3,618.39 | 108,336 | |
Mauro Garry Paul | LFVN | Director | Sep 3 '24 | Buy | $7.40 | 1,600 | $11,848.00 | 77,667 |
LFVN Breaking Stock News: Dive into LFVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Simply Wall St.
12 days ago
Simply Wall St.
15 days ago
GuruFocus.com
19 days ago
Associated Press Finance
19 days ago
GlobeNewswire
19 days ago
GlobeNewswire
19 days ago
GlobeNewswire
19 days ago
The information presented on this page, "LFVN Lifevantage Corporation (Delaware) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.